Abstract OBJECTIVE: To compare the characteristics of immunomagnetic beads and hespan precipitation for isolation of mononuclear cells (MNCs) from umbilical cord blood and try to find a better isolation method for MNCs. METHODS: Fifteen umbilical cord blood samples from healthy parturiens were collected between December 2007 and March 2008. MNCs were isolated using hespan precipitation and CD133 immunomagnetic beads, respectively. MNCs were identified using the surface marker CD34 by flow cytometry on the 30th of primary culture. Growth conditions and morphologic changes of primary cells were observed by an inverted microscope. RESULTS: The number of MNCs from umbilical cord blood isolated by hespan precipitation (15.23±4.30×106/mL) was significantly greater than that by CD133 immunomagnetic beads (0.066±0.027×106/mL) (P<0.05). The MNCs isolated by hespan precipitation suspended at the culture medium and their growth was slow after passage. The growth of MNCs isolated by CD133 immunomagnetic beads was kept in a good condition. The CD34 positive rate of MNCs isolated by hespan precipitation and immunomagnetic beads was 10.1% and 0.5%, respectively. CONCLUSIONS: The hespan precipitation is an effective method for MNCs isolation from human umbilical cord blood, but with a cell growth condition below the mark. The MNCs isolated by CD133 immunomagnetic beads are in a high purity quotient.［Chin J Contemp Pediatr, 2009, 11 (9):757-760］
LI Min,FAN Shu-Yang,SUN Guang-Hui et al. Comparison of immunomagnetic beads and hespan precipitation for isolation of mononuclear cells from umbilical cord blood[J]. 中国当代儿科杂志, 2009, 11(9): 757-760.
LI Min,FAN Shu-Yang,SUN Guang-Hui et al. Comparison of immunomagnetic beads and hespan precipitation for isolation of mononuclear cells from umbilical cord blood[J]. CJCP, 2009, 11(9): 757-760.
［1］Bliss T, Guzman R, Daadi M, Steinberg GK. Cell transplantation therapy for stroke［J］. Stroke, 2007, 38(2 Suppl 1）:817-826.
［2］Kang JH, Lee CK, Kim JR, Yu SJ, Jo JH, Do BR, et al. Estrogen stimulates the neuronal differentiation of human umbilical cord blood mesenchymal stem cells (CD34-)［J］. Neuroreport, 2007, 18(1):35-38.
［3］William T, Kevin DB, Mary JL. Umbilical cord blood transplantation:an alternative for adult patients［J］. Curr Opin Organ Transplant, 2006, 11(1):37-45.
［4］Meier C, Middelanis J, Wasielewski B, Neuhoff S, Roth-Haerer A, Gantert M, et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells［J］. Pediatr Res, 2006, 59(2):244-249.
［9］Atsma DE, Fibbe WE, Rabelink TJ. Opportunities and challenges for mesenchymal stem cell-mediated heart repair［J］. Current Opinion in Lipidol, 2007, 18(6):645-649.
［10］Ouyang HW, Cao T, Zou XH, Heng BC, Wang LL, Song XH, et al. Mesenchymal stem cell sheets revitalize nonviable dense grafts: implications for repair of large-bone and tendon defects［J］. Transplantation, 2006, 82(2):170-174.
［11］Dazzi F, Horwood NJ. Potential of mesenchymal stem cell therapy［J］. Current Opinion Oncol, 2007, 19(6):650-655.
［12］Polisetty N, Fatima A, Madhira SL, Virender SS, Geeta KV. Mesenchymal cells from limbal stroma of human eye［J］. Mol Vis, 2008, 14（4）:431-442.
［13］Yin AH, Miraglia S, Zanjani ED, Graca AP, Makio O, Anne GL, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells［J］. Blood, 1997, 90(12):5002-5012.
［14］Tondreau T, Meuleman N, Delforge A, Marielle D, Rita L, Martine M, et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity［J］. Stem Cells, 2005, 23(8):1105-1112.
［15］Pochampally RR, Smith JR, Ylostalo J, Prockop DJ.Serum deprivation of human stromal cells (hMSCs) selects for a subpopulation of early progenitor cells with enhanced expression of OCT-4 and other embryonic genes［J］.Blood, 2004, 103(5):1647-1652.
